Online inquiry

IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6492MR)

This product GTTS-WQ6492MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6492MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14819MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ9272MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ13657MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ15406MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ10681MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ16000MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ7917MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ6350MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW